Agoracom Blog Home

Posts Tagged ‘Adjuvant’

VIDEO: Mountain Valley MD $MVMD $MVMDF Proceeding With Pre-Clinical Cancer Trials & Files Related Patent $CTLT $MRNA $NVA

Posted by AGORACOM-Eric at 9:51 AM on Wednesday, May 5th, 2021

Mountain Valley MD $MVMD $MVMDF Holdings Inc. Proceeding with Application to List on the TSX Venture Exchange $CTLT $MRNA $NVAX

Posted by AGORACOM-Eric at 8:47 AM on Tuesday, April 20th, 2021

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD“) (CSE: MVMD) (FRA:20MP) (OTCQB: MVMDF) is pleased to announce that it is proceeding with the application for the listing of its shares for trading on the TSX Venture Exchange (“TSXV”).  The Company’s board of directors has approved the move and the Company intends to submit an application to the TSXV this week.

“We believe that pursuing a listing on the TSX-V is a great step for Mountain Valley MD Holdings Inc. and will provide increased liquidity and trading capabilities in MVMD’s common shares for both institutional and retail investors,” stated Dennis Hancock, President and CEO of Mountain Valley MD.  “This is a significant part of our efforts to broaden our appeal to a larger shareholder base and continue to raise the Company’s profile among the North American investment community.”

Completion of the listing on the TSXV is subject to the satisfaction of listing requirements and the approval of the TSXV.  In the meantime, MVMD’s shares will continue to trade on the Canadian Securities Exchange under the ticker symbol “MVMD”.  Further updates will be provided as they become available.

ABOUT MOUNTAIN VALLEY MD HOLDINGS INC
Mountain Valley MD is building a world-class biotech and life sciences company organization centred around the implementation of its patented Quicksome™ oral drug formulation and delivery technologies and its Quicksol™ solubilization technology for macrocyclic lactones, to innovate industry leading products that are sought out globally.

MVMD’s proposition for delivering Quicksome™ formulations that have rapid onset, high bioavailability, low variability and precision dosing is core to the Company’s success across key health and wellness categories. Consistent with its vision towards “Helping People Live Their Best Life”, MVMD applies its Quicksome™ and Quicksol™ technologies to its ground-breaking work for advanced delivery of vaccines and pharmaceutical drugs as well as the development of products for pain management, weight loss, energy, focus, sleep, anxiety, and more.

The Company’s patented Quicksome™ desiccation technology utilizes advanced liposomes and other stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats that are consumed orally.  The result is a new generation of product formulations that are capable of delivering vaccines, drugs and nutraceuticals into the body faster, with greater impact, efficiency and accuracy. 

Read More: https://agoracom.com/ir/MountainValleyMD/forums/discussion/topics/759352-mountain-valley-md-holdings-inc-proceeding-with-application-to-list-on-the-tsx-venture-exchange/messages/2312668#message

Mountain Valley MD $MVMD $MVMDF Commencing Trials in Bangladesh, Striking Pharmaceutical Production Agreements $CTLT $MRNA $NVAX

Posted by AGORACOM-Eric at 10:31 AM on Tuesday, March 16th, 2021

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD“) (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce it is commencing husbandry animal trials under the supervision of The People’s Republic of Bangladesh’s Ministry of Fisheries & Livestock for the Company’s injectable solubilized Ivermectin technology, Ivectosol™ 1%.

“We are very excited to be welcoming Mountain Valley MD to The People’s Republic of Bangladesh and are proud that they have selected our country for important research projects and as a key production hub for its solubilized Ivectosol™ 1% product,” stated Bangladesh’s Foreign Minister H.E. Dr. A. K. Abdul Momen, M.P.

MVMD is working with its local partner R&G Group inside Bangladesh to quickly advance its research and development, and manufacturing capabilities inside the country.

MVMD’s Ivectosol™ 1%, a fully solubilized form of the anti-parasitic drug Ivermectin, will be tested in cattle, goat and poultry under the supervision of the Bangladesh Government’s approved and authorized laboratories and research institutes.  The tests will be conducted by way of intra-muscular needleless injection of Ivectosol™ 1% in an effort to demonstrate superior pharmacokinetics in terms of CMAX (peak serum concentration that a drug achieves) and AUC (area under the curve) with advanced drug withdrawal time control, versus current commercially available forms.

The trials are scheduled to commence in early April, 2021 and are anticipated to take 30 days.  The trial results are scheduled to be reviewed and approved by the Ministry of Fisheries & Livestock and Ministry of Health and will enable the Company to advance against immediate commercialization opportunities.  The Company is finalizing production supply agreements with key Bangladesh pharmaceutical partners to produce its Ivectosol™ 1% for use and distribution throughout Bangladesh and as a production hub for broader global distribution.  The production scheduling and pricing are currently being finalized under non-disclosure agreement (“NDA”), including securing the sufficient Ivermectin Active Pharmaceutical Ingredient (“API”) quantity for anticipated global demand.

“We’ve been extremely impressed by the speed and pace with which the Government of the People’s Republic of Bangladesh continues to provide our teams with incredible support for the testing and preparedness of an accelerated commercialization pathway for Ivectosol™ 1%,” stated Dennis Hancock, President and CEO of Mountain Valley MD.  “Our pharmaceutical partners are both FDA and EU compliant and support our broader objectives to scale for global production.  Securing top quality manufacturing within a competitive cost structure is critical to align with one of the core tenets of MVMD’s mission to ensure accessibility to our technology for even the most disadvantaged nations.”

Read More: https://agoracom.com/ir/MountainValleyMD/forums/discussion/topics/757425-mountain-valley-md-commencing-trials-in-bangladesh-striking-pharmaceutical-production-agreements/messages/2308370#message

Mountain Valley MD $MVMD $MVMDF Achieves Solubilization of Selamectin, Files Trademark For Selactosol™ $CTLT $MRNA $NVAX

Posted by AGORACOM-Eric at 10:15 AM on Wednesday, March 10th, 2021
  • Mountain Valley MD Files Trademark For Selactosol™

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD“) (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce it has achieved a water solubilized selamectin product using its patent-pending Quicksol™ technology.  To date, selamectin was considered a virtually water insoluble molecule with tremendous potential in treating parasitic infestations in husbandry and companion animals, as well as mycobacterium-based infections including Buruli Ulcer, Leprosy and Tuberculosis.

MVMD scientists successfully solubilized selamectin at 15mg/ml into a water solution without any organic solvents, which it believes is a critical achievement to allow formulation into topical application creams, oral rapid dissolve sublingual tablets, and injectable applications.

“We continue to accelerate our focus and efforts on solving the most significant human and husbandry animal health problems facing our global population,” stated Dennis Hancock, President and CEO of Mountain Valley MD.  “We are very optimistic that this breakthrough on selamectin will help MVMD pursue near term licensing and commercialization opportunities consistent with our business plan.”

The Company has filed for trademark protection under the brand name Selactosol™ to support its continuing work within the Quicksol™ line of water solubilized macro-cyclic lactones.  The Company has focused its initial efforts on already approved macro-cyclic lactones given its belief that they will yield the broadest commercialization opportunities in the shortest period of time.

Having successfully applied the Quicksol™ solubilization technique to the selamectin drug, MVMD will now proceed to formulate Selactosol™ 1.5% for preclinical evaluation trials of mycobacterium-based infections such as Buruli Ulcer, Leprosy and Tuberculosis.

“We believe this discovery to be a breakthrough that will enable the efficacy needed to treat respiratory infections such as tuberculosis by enabling the drug deposition into the airways and lungs through injections, aerosol formulations and pulmonary delivery,” stated Mike Farber, Director of Life Sciences at Mountain Valley MD.  “We are anxiously looking forward to proving the efficacy of this breakthrough in multi-drug and extended drug resistant strains of tuberculosis.”

Read More: https://agoracom.com/ir/MountainValleyMD/forums/discussion/topics/756963-mountain-valley-md-achieves-solubilization-of-selamectin-files-trademark-for-selactosol/messages/2307352#message

VIDEO – Mountain Valley MD $MVMD $MVMDF FDA Application First Step Toward Human Applications For Game Changing Ivectosol™ $CTLT $MRNA $NVAX

Posted by AGORACOM-JC at 5:30 PM on Wednesday, March 3rd, 2021

Mountain Valley MD takes existing Vaccines & Drugs and delivers them better. Into the body better and by transportation. MVMD’s solubility technology applied to the Ivermectin drug is the only form in the world that are currently approved by the US Food and Drug Administration (FDA), making it a leading candidate for human injection and sublingual applications.

To this end they have created Ivectosol™ and it could be a massive disruption in the Vaccine Industry.

If you are looking to learn more about vaccine technologies. This video is a must watch with Dennis Hancock & Mike Farber of MVMD.

See how Mountain Valley MD is doing more with less. 

Mountain Valley MD $MVMD $MVMDF Proceeding with FDA Pathway Application for Novel Ivectosol™ $CTLT $MRNA $NVAX

Posted by AGORACOM-Eric at 9:54 AM on Wednesday, March 3rd, 2021
This image has an empty alt attribute; its file name is MVMD-Small.png

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD“) (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce it has contracted Camargo Pharmaceutical Services, LLC (“Camargo”) to provide regulatory consulting services to support MVMD’s pursuit of U.S. Food and Drug Administration (FDA) approval of its novel Ivectosol™ rapid dissolve oral format.

Camargo is recognized as one of the most experienced global organizations who specialize in drug and combination device product development and approval utilizing the regulatory pathway provided for in Section 505(b)(2) of the US Federal Food, Drug, and Cosmetic Act.  Over the last decade, Camargo has established a leading track record with 505(b)(2) investigational new drug (“IND”) and new drug applications (“NDA” preparations and submissions, including participation in more than 1100 Agency meetings and more than 200 FDA NDA and ANDA (Abbreviated New Drug Applications) approvals.

“After successful pre-clinical studies of our novel solubilized Ivectosol™ sublingual in our pre-clinical trials, this is a critical next step in the approval process to support our human application objectives,” stated Mike Farber, Director of Life Sciences at Mountain Valley MD.   “Camargo will be a great partner to accelerate our efforts for the initial pre-IND presentation to the FDA outlining Ivermectin’s prior usage history and extensive safety record for the FDA’s assessment and approval pathway.”

The 505(b)(2) new drug application is one of three U.S. Food and Drug Administration drug approval pathways and represents an appealing regulatory strategy by way of helping to avoid unnecessary duplication of studies already performed on a previously approved drug.  The Company believes the 505(b)(2) pathway will result in a much less expensive and much faster route to approval, compared with a traditional development pathway, while creating a new, differentiated Ivermectin product with tremendous commercial value.

“Camargo is proud to partner with Mountain Valley MD to advance their novel solubilized Ivermectin sublingual wafer,” said Catherine Gatza, PhD, Vice President, Regulatory and Strategy at Camargo. “This program delivers important advantages to the parasitic infection treatment landscape by providing an alternative dosage form.”

As previously communicated, MVMD’s solubility technology applied to the Ivermectin drug is the only form in the world that uses strictly excipients that are currently approved by the US Food and Drug Administration (FDA), making it a leading candidate for human injection and sublingual applications as well as significantly broader husbandry and companion animal treatments based on its low viscosity.

“The U.S. FDA approval would prove the efficacy and safety of MVMD’s Ivectosol™ wafer at one of the highest standards in the world and would assist in facilitating greater access to key global markets in an accelerated capacity,” stated Dennis Hancock, President & CEO of Mountain Valley MD.  “The human approval pathway timed with our aggressive pursuit of husbandry applications, is core to making our Ivectosol™ products the number one commercial form of Ivermectin in the world.”

Read More: https://agoracom.com/ir/MountainValleyMD/forums/discussion/topics/756473-mountain-valley-md-proceeding-with-fda-505-b-2-pathway-application-for-novel-ivectosol/messages/2306213#message

Mountain Valley MD $MVMD $MVMDF Commencing Husbandry Animal Trials, Appoints Seasoned Doctor of Veterinary Medicine to Advisory Board $CTLT $MRNA $NVAX

Posted by AGORACOM-Eric at 9:23 AM on Monday, March 1st, 2021
This image has an empty alt attribute; its file name is MVMD-Small.png

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD“) (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce it is commencing husbandry animal trials with a third-party preclinical contract research organization (“CRO”) to validate the superiority of the Company’s injectable solubilized Ivermectin technology, Ivectosol™ 1%, versus current commercially available forms to treat a broad category of animal parasites.

MVMD’s Ivectosol 1% will be tested in swine and poultry by way of advanced intra-muscular needleless injection to prove superior pharmacokinetics in terms of CMAX (peak serum concentration that a drug achieves) and AUC (area under the curve) with targeted drug withdrawal times within 10 days of administration.  Additionally, the study is anticipated to demonstrate superior ease of administration with elimination of typically heavy restraint requirements, elimination of injection pain for the animal, while dramatically reducing the risk of potentially fatal clostridial infection common with traditional injection site penetration from large gauge needles.

“This is a very significant project that will move very quickly and will form the basis for our submissions in new animal drug applications to the Food and Drug Administration,” stated Dennis Hancock, President and CEO of Mountain Valley MD.  “With our solubilized Ivectosol™1% solution, we will be able to pursue new injectable markets for Ivermectin such as game and poultry that doesn’t exist today, opening up tens-of-billions of animal applications globally per year.”

The Company’s Ivectosol 1% solution uses no harmful organic solvents and is the viscosity of water, which enables novel needleless injector applications.  The Company believes the use of needle-free injection systems with a solubilized Ivermectin will deliver significant benefits to livestock and poultry producers, including increased efficacy and elimination of needles that transfer disease and risk of breaking into food supply, improved administration simplicity with reduced labour and safer handling protocols, minimized tissue damage that traditionally negatively impacts yields, and precision dosing that helps to eliminate human error.

Proceeding with the animal trial is part of the Company’s plan to pursue the broad husbandry and companion animal markets with its Ivectosol™ 1% technology, focused immediately on cattle, swine and poultry industries with a combined annual consumption market size of more than 67 billion animals.

Additionally, the Company is pleased to announce the introduction of Michel Rondeau, Doctor of Veterinary Medicine, as an advisor who will be overseeing the study and driving global pharmaceutical husbandry applications as part of the ongoing business commercialization of MVMD’s technology.

Dr. Rondeau has extensive experience in veterinary research having worked with numerous pharmaceutical companies in animal drug field trials and is credited with co-inventing a global award winning sprayable vaccination device that was acquired by Rhone Poulenc.  Dr. Rondeau has completed an extensive range of research and development projects across a diverse range of husbandry animals including porcine industrial medicine across preventative and curative medicine, nutrition and animal health products and automated feed systems.

Read More: https://agoracom.com/ir/MountainValleyMD/forums/discussion/topics/756293-mountain-valley-md-commencing-husbandry-animal-trials-appoints-seasoned-doctor-of-veterinary-medicine-to-advisory-board/messages/2305890#message

Mountain Valley MD $MVMD $MVMDF Confirms Quicksome™ License Agreement, First Revenues $CTLT $MRNA $NVAX

Posted by AGORACOM-Eric at 9:18 AM on Thursday, February 25th, 2021
This image has an empty alt attribute; its file name is MVMD-Small.png
  • Entered a commercial license agreement with that is focused on the rapidly emerging global mushroom space.
  • Based on applying MVMD’s Quicksome™ technology to mushroom nutraceutical products
  • Initial payment in the amount of $250,000 CAD

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD“) (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce that Mountain Valley MD Inc. (“Mountain Valley“) has finalized and entered into a commercial license agreement with Circadian Wellness Corp. (“Circadian“), a privately held Ontario corporation that is focused on the rapidly emerging global mushroom space.

The license agreement with Circadian is based on applying MVMD’s Quicksome™ technology to mushroom nutraceutical products in consideration of ongoing product royalties and an initial payment in the amount of $250,000 CAD, made up of $200,000 CAD cash and $50,000 CAD of equity shares in Circadian.  The initial payment monies will be applied to formulation, product development and sample development work and represents the Company’s first revenues.

MVMD has been working closely with Circadian on proprietary formulations for mushroom-infused products that achieved a significant increase in overall molecule efficacy with the Company’s Quicksome™ desiccated liposome technology applied across a variety of rapid dissolve oral products.  Circadian is finalizing its product plans and go-to-market strategy for a broad line of naturally derived mushroom products that will be distributed initially in North America and expanded globally in future phases.

“Embedding Mountain Valley MD’s Quicksome™ technology into our unique mushroom product formulations has allowed us to create a product line that we believe will be unmatched in its efficacy in the marketplace,” stated Dr. Sanjeev Goel, Chief Medical Officer at Circadian Wellness and founder of Peak Human Labs. “The initial consumer testing with our energy and sleep products has been very well received.  The precision of this delivery technology allows us to build the functional mushroom business out while simultaneously pursuing a leadership position in the rapidly emerging psychedelic space.”

Circadian is a privately held Ontario corporation in the business of mushroom cultivation, extraction, clinical research and development, and end-user consumer health and wellness products and retreats (www.circadianwellness.com).

“With our focus on providing our global nutraceutical, vaccine and pharmaceutical partners with unprecedented product and market advantages, we believe our partnership with Circadian Wellness is a perfect bullseye for our value proposition across the health and wellness space,” stated Dennis Hancock, President and CEO of Mountain Valley MD.  “This inroad into the rapidly growing mushroom industry timed with the broadening analyst coverage of the numerous scientific benefits of mushrooms on human health are expected to be significant for our business plan at Mountain Valley MD.”

“Our ability to drive an increase in bioavailability across convenient and easy-to-use rapid dissolve oral delivery formats provides numerous product advantages that we believe will position Circadian Wellness products as the preeminent choice for consumers in the rapidly growing mushroom marketplace,” stated Mike Farber, Director of Life Sciences at Mountain Valley MD.

Read More: https://agoracom.com/ir/MountainValleyMD/forums/discussion/topics/756066-mountain-valley-md-confirms-quicksome-license-agreement-first-revenues/messages/2305344#message

Mountain Valley MD $MVMD $MVDMF to Include Testing of South African Mutation in Upcoming COVID-19 BSL-4 Clearance Work $CTLT $MRNA $NVAX

Posted by AGORACOM-Eric at 9:29 AM on Monday, February 22nd, 2021
  • Testing South African COVID-19 variant with the Company’s new solubilized Ivermectin technology.
  • Mutation is now the most dominant form of the COVID-19 virus in South Africa

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce that it will be testing the new B.1.351 South African COVID-19 variant in its upcoming Bio Safety Level 4 (“BSL-4”) lab study, which is analyzing viral clearance efficacy with the Company’s new solubilized Ivermectin technology.

According to the World Health Organization*, the mutated B.1.351 COVID-19 variant is now the most dominant form of the COVID-19 virus in South Africa and is believed to be more infectious and thus easier to spread. As the COVID-19 virus continually mutates, researchers are assessing the impact of the current vaccines that are in distribution to understand if they may be rendered less effective or even noneffective**.

“We felt it was critical to look at this new South African COVID-19 variant given the immediate complexities we are seeing with the pace of vaccine rollout and the high probability that current vaccines will not be as effective, if at all, against these emerging mutations,” stated Dennis Hancock, President and CEO of Mountain Valley MD. “It is important to us across our broad human health objectives that our solubilized Ivermectin technology can be confidently applied as the broadest COVID-19 therapeutic and number one choice in the world when a vaccine falls short.”

The Company has previously communicated that it believes its solubilized Ivermectin would be suitable for a broad therapeutic across a wide range of viruses in the future, not just limited to COVID-19.

“It is not clear if the current vaccines will protect you from the new variants and early information is that vaccines are not as effective on the mutations. We are attempting in our work with the BSL-4 lab to target novel COVID-19 variants that would prove Ivermectin’s broad activity in interfering with the replication of the virus and thus broadly applies across multiple variants versus being specific to a variant the way a vaccine would be,” stated Mike Farber, Director of Life Sciences at MVMD.

As communicated in the Company’s news release on January 27, 2021, the BSL-4 trial will be the first of its kind ever conducted with human grade solubilized Ivermectin anywhere in the world and its design was led by the Company’s key scientific advisor, Dr. John Clements. Dr. Clements is Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine and has over 35 years of experience in vaccine, immunology and infectious diseases research and development, with a distinguished scientific career focused on developing and evaluating vaccines for a wide range of infectious diseases globally.

Read More: https://agoracom.com/ir/MountainValleyMD/forums/discussion/topics/755796-mountain-valley-md-to-include-testing-of-south-african-mutation-in-upcoming-covid-19-bsl-4-clearance-work/messages/2304707#message

Mountain Valley MD $MVMD.ca to Commence Trading on OTCQB Market Under Ticker MVMDF $CTLT $MRNA $NVAX

Posted by AGORACOM-Eric at 1:33 PM on Friday, February 12th, 2021

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD“) (CSE: MVMD) (FRA: 20MP) is pleased to announce that effective February 16, 2021, it will graduate from the OTC Pink Sheets (“OTCPK”) and commence trading on the OTCQB Venture Marketplace (“OTCQB”) under the symbol “MVMDF”. 

The OTCQB is operated by OTC Markets Group Inc. (“OTC”) out of New York City, NY.  The OTC operates the world’s largest electronic interdealer quotation system for US broker dealers and offers multiple media channels to increase the visibility of OTC-listed companies.  Trading on the OTCQB Market enables companies to efficiently build broader investor awareness and provide U.S. investors with a seamless trading facility to more easily trade through the broker of their choice.

Investors can find Real-Time quotes and market information for MVMD on www.otcmarkets.com.  The Company continues to trade on the Canadian Securities Exchange under the ticker symbol “MVMD” and the Frankfurt Stock Exchange under the ticker symbol “20MP”.

“Trading on the OTCQB is an excellent advancement that will provide a large U.S. investor base with the opportunity to participate directly in Mountain Valley MD’s growth,” stated Dennis Hancock, President and CEO of Mountain Valley MD Holdings.  “The OTC listing will contribute to our strategy to continue to enhance our share liquidity and broaden the reach and awareness of our global health and wellness innovations.”

Read More: https://agoracom.com/ir/MountainValleyMD/forums/discussion/topics/755263-mountain-valley-md-holdings-to-commence-trading-on-otcqb-market-under-ticker-mvmdf/messages/2303455#message